Abstract

High levels of cholesterol are a primary risk factor in the development of cardiovascular diseases. In this review, we have summarized the structural, chemical and computational aspects of hypocholesterolemic drugs, both statins and non-statins, that target enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) to block cholesterol biosynthesis.

Keywords: 3-hydroxy-3-methylglutaryl-coenzyme A reductase, α-asarone, cardiovascular disease, low density lipoproteins, cholesterol, statins, side effects, structure-based drug design